Could the Pfizer acquisition of Arena be a sign of things to come in Big Pharma?

Analysts expect further Big Pharma acquisitions of companies involved in the development of cannabinoid treatments to become commonplace as the promising results and growth potential of medical cannabis continue to attract interest.

However, while these acquisitions are expected to propel and expand cannabinoid treatment options, the overall impact of and interest in Big Pharma’s reach into the industry remains a matter of speculation.